ANAB Stock Analysis: AnaptysBio | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.845m USD | 12M Return: 330.7% | Charts, Fundamentals & Technical Analysis

Antibody Therapeutics, Autoimmune Diseases, Oncology, Inflammation
Total Rating 58
Safety 41
Buy Signal 1.49
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.84B
Avg Turnover: 33.5M
Risk 3d forecast
Volatility80.2%
VaR 5th Pctl11.4%
VaR vs Median-11.0%
Reward TTM
Sharpe Ratio2.38
Rel. Str. IBD98.7
Rel. Str. Peer Group89.3
Character TTM
Beta0.699
Beta Downside-0.308
Hurst Exponent0.554
Drawdowns 3y
Max DD69.32%
CAGR/Max DD1.04
CAGR/Mean DD3.33
EPS (Earnings per Share) EPS (Earnings per Share) of ANAB over the last years for every Quarter: "2021-06": -0.02, "2021-09": -0.24, "2021-12": -1.13, "2022-03": -1.31, "2022-06": -1.15, "2022-09": -1.18, "2022-12": -0.93, "2023-03": -1.58, "2023-06": -1.5, "2023-09": -1.41, "2023-12": -1.59, "2024-03": -1.64, "2024-06": -1.71, "2024-09": -1.14, "2024-12": -0.72, "2025-03": -1.28, "2025-06": -1.34, "2025-09": 0.52, "2025-12": 1.58, "2026-03": -1.8432,
Last SUE: -1.03
Qual. Beats: -1
Revenue Revenue of ANAB over the last years for every Quarter: 2021-06: 30.027, 2021-09: 20.89, 2021-12: 1.010999, 2022-03: 0.97, 2022-06: 1.216, 2022-09: 1.293, 2022-12: 6.808, 2023-03: 1.374, 2023-06: 3.46, 2023-09: 3.318, 2023-12: 9.005, 2024-03: 7.179, 2024-06: 10.971, 2024-09: 30.017, 2024-12: 43.113, 2025-03: 27.771, 2025-06: 22.263, 2025-09: 76.32, 2025-12: 108.249, 2026-03: 25.556,
Rev. CAGR: 229.91%
Rev. Trend: 98.7%
Last SUE: 0.32
Qual. Beats: 0

Warnings

Negative Equity With Losses: Insolvent Profile
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Choppy

Tailwinds

Rs Leader
Idiosyncratic Leader
Tailwind
Avwap Ph Week

Seasonality 9.4 years of data

Jan -8.2% 10
Feb +3.5% 19
Mar -10.2% 36
Apr +6.0% 9
May -6.5% 38
Jun +4.8% 9
Jul -1.8% 12
Aug +1.4% 18
Sep -3.2% 15
Oct +8.1% 17
Nov -5.6% 30
Dec +1.6% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ANAB AnaptysBio

AnaptysBio is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, headquartered in San Diego, California and incorporated in 2005. As a clinical-stage biotech, the company does not yet generate commercial product revenue and relies on pipeline advancement and partner collaborations to drive valuation.

Its lead clinical asset, Rosnilimab, completed a Phase 2b trial in moderate-to-severe rheumatoid arthritis, while earlier-stage programs include ANB033 (CD122 antagonist), ANB101 (BDCA2 modulator targeting plasmacytoid dendritic cells), and Imsidolimab (IL-36 receptor antagonist in Phase 3 for generalized pustular psoriasis). The company also retains rights to dostarlimab, a PD-1 antagonist being explored across solid tumor indications.

AnaptysBio operates a partnership-driven business model, with collaboration agreements in place with larger pharmaceutical companies GSK and Vanda to help fund and advance its antibody programs through preclinical and clinical milestones.

Headlines to Watch Out For
  • Rosnilimab Phase 2b rheumatoid arthritis data readout approaches
  • Imsidolimab Phase 3 GPP trial enrollment drives near-term catalyst
  • GSK Jemperli dostarlimab royalty revenue scales on oncology launch
  • Rising R&D cash burn pressures runway amid pipeline advancement
Piotroski VR-10 (Strict) 4.0
Net Income: -26.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 30.06 > 1.0
NWC/Revenue: 118.1% < 20% (prev 285.2%; Δ -167.1% < -1%)
CFO/TA 0.01 > 3% & CFO 4.48m > Net Income -26.8m
Net Debt (4.51m) to EBITDA (58.5m): 0.08 < 3
Current Ratio: 7.58 > 1.5 & < 3
Outstanding Shares: last quarter (28.7m) vs 12m ago -6.37% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 61.83% > 50% (prev 26.51%; Δ 35.32% > 0%)
Interest Coverage Ratio: 0.68 > 6 (EBIT TTM 56.1m / Interest Expense TTM 82.7m)
Altman Z'' -1.66
A: 0.83 (Total Current Assets 316.1m - Total Current Liabilities 41.7m) / Total Assets 329.7m
B: -2.50 (Retained Earnings -825.4m / Total Assets 329.7m)
C: 0.15 (EBIT TTM 56.1m / Avg Total Assets 375.9m)
D: 0.04 (Book Value of Equity 12.7m / Total Liabilities 316.9m)
Altman-Z'' = -1.66 = D
Beneish M -3.10
DSRI: 0.69 (Receivables 25.7m/17.9m, Revenue 232.4m/111.9m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.01 (AQ_t 0.00 / AQ_t-1 0.10)
SGI: 2.08 (Revenue 232.4m / 111.9m)
TATA: -0.09 (NI -26.8m - CFO 4.48m) / TA 329.7m)
Beneish M = -3.10 (Cap -4..+1) = AA
What is the price of ANAB shares?

As of July 08, 2026, the stock is trading at USD 67.33 with a total of 947,033 shares traded. Over the past week, the price has changed by +2.05%, over one month by +31.08%, over three months by +62.54% and over the past year by +330.65%.

Current recommended Stop Loss: 63.60 (which is 5.5% or 1.1 ATR below the current price).

Is ANAB a buy, sell or hold?

AnaptysBio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy ANAB.

  • StrongBuy: 7
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ANAB price?
Analysts Target Price 87.1 29.3%
AnaptysBio (ANAB) - Fundamental Data Overview as of 08 July 2026
Market Cap USD = 1.84b (1.84b USD * 1.0 USD.USD)
P/S = 7.9389
P/B = 147.3107
Revenue TTM = 232.4m USD
EBIT TTM = 56.1m USD
EBITDA TTM = 58.5m USD
Long Term Debt = 275.2m USD (estimated: total debt 277.4m - short term 2.12m)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 291.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.6m
Net Debt = 4.51m USD (calculated: Debt 291.0m - CCE 286.5m)
Enterprise Value = 1.85b USD (1.84b + Debt 291.0m - CCE 286.5m)
Interest Coverage Ratio = 0.68 (Ebit TTM 56.1m / Interest Expense TTM 82.7m)
EV/FCF = 110.8x (Enterprise Value 1.85b / FCF TTM 16.7m)
FCF Yield = 0.90% (FCF TTM 16.7m / Enterprise Value 1.85b)
FCF Margin = 7.18% (FCF TTM 16.7m / Revenue TTM 232.4m)
Net Margin = -11.53% (Net Income TTM -26.8m / Revenue TTM 232.4m)
 Gross Margin = unknown ((Revenue TTM 232.4m - Cost of Revenue TTM 2.42m) / Revenue TTM)
 Tobins Q-Ratio = 5.61 (Enterprise Value 1.85b / Total Assets 329.7m)
Interest Expense / Debt = 28.42% (Interest Expense 82.7m / Debt 291.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 44.3m (EBIT 56.1m * (1 - 21.00%))
Current Ratio = 6.42 (Total Current Assets 316.1m / Total Current Liabilities 49.2m)
Debt / Equity = 22.83 (Debt 291.0m / totalStockholderEquity, last quarter 12.7m)
Debt / EBITDA = 0.08 (Net Debt 4.51m / EBITDA 58.5m)
Debt / FCF = 0.27 (Net Debt 4.51m / FCF TTM 16.7m)
Total Stockholder Equity = -6.05m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.13% (Net Income -26.8m / Total Assets 329.7m)
 RoE = 442.9% (negative equity) (Net Income TTM -26.8m / Total Stockholder Equity -6.05m)
 RoCE = 20.83% (EBIT 56.1m / Capital Employed (Equity -6.05m + L.T.Debt 275.2m))
RoIC = 15.90% (NOPAT 44.3m / Invested Capital 278.5m)
WACC = 10.35% (E(1.84b)/V(2.14b) * Re(8.44%) + D(291.0m)/V(2.14b) * Rd(28.42%) * (1-Tc(0.21)))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.11 | Cagr: 3.44%
[DCF] Terminal Value 68.76% ; FCFF base≈16.7m ; Y1≈16.8m ; Y5≈17.8m
[DCF] Fair Price = 6.81 (EV 206.1m - Net Debt 4.51m = Equity 201.6m / Shares 29.6m; r=10.35% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.03 | # QB: -1
Revenue Correlation: 98.68 | Revenue CAGR: 229.9% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.14 | Chg30d=-49.93% | Revisions=-57% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.38 | Chg30d=-21.26% | Revisions=-57% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.23 | Chg30d=-125.94% | Revisions=-57% | GrowthEPS=+49.8% | GrowthRev=-53.1%
EPS next Year (2027-12-31): EPS=5.24 | Chg30d=+7.18% | Revisions=+0% | GrowthEPS=+2369.2% | GrowthRev=+39.7%
[Analyst] Revisions Ratio: -63% (up=2, down=14)